Procalcitonin for the clinical laboratory: a review
- 1 August 2007
- Vol. 39 (4) , 383-390
- https://doi.org/10.1080/00313020701444564
Abstract
Procalcitonin measurement has been claimed as a helpful marker in bacterial infection and sepsis. It has obtained FDA approval and is now widely marketed in the United States and Europe. This review summarises the current assays available, the evidence for its use and possible future applications of the assay.Keywords
This publication has 74 references indexed in Scilit:
- Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind studyBMJ, 2006
- Proinflammatory cytokines and procalcitonin in children with acute pyelonephritisPediatric Nephrology, 2005
- Use of Procalcitonin and C-Reactive Protein to Evaluate Vaccine Efficacy against PneumoniaPLoS Medicine, 2005
- Biological Variation of Procalcitonin in Healthy IndividualsClinical Chemistry, 2004
- Procalcitonin as a prognostic marker in children with meningococcal septic shockArchives of Disease in Childhood, 2002
- Assessment of Procalcitonin as a Diagnostic Marker of Underlying Infection in Patients with Febrile NeutropeniaClinical Infectious Diseases, 2001
- Procalcitonin: a new marker of inflammation in haemodialysis patients?Nephrology Dialysis Transplantation, 2001
- Calcitonin precursors are reliable markers of sepsis in a medical intensive care unitCritical Care Medicine, 2000
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992